Advances in the management of pulmonary arterial hypertension, including early initiation of combination therapies, have increased 1-year survival rates to 86%-90% and average long-term survival to 6 years.
This review summarizes recent advances in the screening, diagnosis, and management of pulmonary arterial hypertension, emphasizing the shift towards early aggressive combination therapy and precision medicine.
The management of pulmonary arterial hypertension (PAH) has significantly evolved over the last decades in the wake of more sensitive diagnostics and specialized clinical programs that can provide focused medical care. In the current era of PAH care, 1-year survival rates have increased to 86%-90% from 65% in the 1980s, and average long-term survival has increased to 6 years from 2.8 years. The heterogeneity in the etiology and disease course has opened doors to focusing research in phenotyping the disease and understanding the pathophysiology at a cellular and genetic level. This may eventually lead to precision medicine and the development of medications that may prevent or reverse pulmonary vascular remodeling. With more insight, clinical trial designs and primary end-points may change to identify the true survival benefit of pharmacotherapy. Identifying responders from non-responders to therapy may help provide individualized patient-centered care rather than an algorithm-based approach. The purpose of this review is to highlight the latest advances in screening, diagnosis, and management of PAH.
Deshwal et al. (Mon,) conducted a review in Pulmonary arterial hypertension. Advances in PAH management was evaluated. Advances in the management of pulmonary arterial hypertension, including early initiation of combination therapies, have increased 1-year survival rates to 86%-90% and average long-term survival to 6 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: